Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine
Recruiting
Observational Study
Meningoccocal Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 7 – 36
- Sex
- Any
- Study type
- Observational
- Participants needed
- 450 (estimated)
- Sponsor
- Serum Institute of India Pvt. Ltd. · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Written informed consent and assent (if applicable)
Exclusion Criteria:
* Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination
* Any condition or criteria that in the opinion of the investigator might compr…
Contacts